Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher D Miller

Showing results (1-10 of 70) with videos related to

Pageof 7
Sort By:
HIV/AIDS (Auckland, N.Z.)|May 10, 2012
New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovirNimish Patel, Christopher D Miller
Kidney International|December 11, 2002
Gender differences in outcomes of arteriovenous fistulas in hemodialysis patientsChristopher D Miller, Michelle L Robbin, Michael Allon
The Annals of Pharmacotherapy|March 10, 2011
Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimensNimish Patel, Sandra Abdelsayed, Michael Veve, et al.
Journal of the American Pharmacists Association : Japha|October 18, 2016
Impact of a pharmacist-driven beta-lactam allergy interview on inpatient antimicrobial therapy: A pilot projectNicholas S Sigona, Jeffrey M Steele, Christopher D Miller
Journal of the American Society of Nephrology : JASN|October 22, 2003
Comparison of arteriovenous grafts in the thigh and upper extremities in hemodialysis patientsChristopher D Miller, Michelle L Robbin, Jill Barker, et al.
The Annals of Pharmacotherapy|November 22, 2013
Evaluation of dabigatran utilization and risk among hospitalized patientsEric Sidman, Luke A Probst, William Darko, et al.
The Journal of Pediatric Pharmacology and Therapeutics : JPPT : the Official Journal of PPAG|March 2, 2018
Significant Hyperbilirubinemia and Acute Hepatocellular Jaundice in a Pediatric Patient Receiving Deferasirox: A Case ReportElizabeth A Feldman, Christopher D Miller, Sarabeth Wojnowicz, et al.
Pharmacotherapy|May 24, 2006
Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofunginChristopher D Miller, Ben W Lomaestro, Steven Park, et al.
The Annals of Pharmacotherapy|December 10, 2009
Nonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agentsJessica Adams, Nimish Patel, Nancy Mankaryous, et al.
Pharmacotherapy|September 28, 2007
Prevalence and risk factors for clinically significant drug interactions with antiretroviral therapyChristopher D Miller, Ramy El-Kholi, John J Faragon, et al.
Pageof 7

Showing results (1-10 of 70) with videos related to

Sort By:
Pageof 7
HIV/AIDS (Auckland, N.Z.)|May 10, 2012
New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovirNimish Patel, Christopher D Miller
Kidney International|December 11, 2002
Gender differences in outcomes of arteriovenous fistulas in hemodialysis patientsChristopher D Miller, Michelle L Robbin, Michael Allon
The Annals of Pharmacotherapy|March 10, 2011
Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimensNimish Patel, Sandra Abdelsayed, Michael Veve, et al.
Journal of the American Pharmacists Association : Japha|October 18, 2016
Impact of a pharmacist-driven beta-lactam allergy interview on inpatient antimicrobial therapy: A pilot projectNicholas S Sigona, Jeffrey M Steele, Christopher D Miller
Journal of the American Society of Nephrology : JASN|October 22, 2003
Comparison of arteriovenous grafts in the thigh and upper extremities in hemodialysis patientsChristopher D Miller, Michelle L Robbin, Jill Barker, et al.
The Annals of Pharmacotherapy|November 22, 2013
Evaluation of dabigatran utilization and risk among hospitalized patientsEric Sidman, Luke A Probst, William Darko, et al.
The Journal of Pediatric Pharmacology and Therapeutics : JPPT : the Official Journal of PPAG|March 2, 2018
Significant Hyperbilirubinemia and Acute Hepatocellular Jaundice in a Pediatric Patient Receiving Deferasirox: A Case ReportElizabeth A Feldman, Christopher D Miller, Sarabeth Wojnowicz, et al.
Pharmacotherapy|May 24, 2006
Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofunginChristopher D Miller, Ben W Lomaestro, Steven Park, et al.
The Annals of Pharmacotherapy|December 10, 2009
Nonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agentsJessica Adams, Nimish Patel, Nancy Mankaryous, et al.
Pharmacotherapy|September 28, 2007
Prevalence and risk factors for clinically significant drug interactions with antiretroviral therapyChristopher D Miller, Ramy El-Kholi, John J Faragon, et al.
Pageof 7